Frequency of compound genotypes associated with β-blocker efficacy in congestive heart failure

Pharmacogenomics

Volumn 5, Issue 5, 2004, Pages 553-558

  Lanfear, David E ^a   Marsh, Sharon ^a   Cresci, Sharon ^a   Spertus, John A ^b   McLeod, Howard L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

blockers; Adrenoceptors; Angiotensin converting enzyme; Heart failure; Pharmacogenetics; Polymorphisms

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; GENOMIC DNA;

AFRICAN AMERICAN; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; EUROPEAN AMERICAN; GENE SEQUENCE; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PREDICTION; PROTEIN ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; AFRICAN AMERICANS; CHI-SQUARE DISTRIBUTION; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOTYPE; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 3543093199     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.5.553     Document Type: Article

References (25)

1. Jessup M, Brozena S: Heart failure. N. Engl. J. Med. 348, 2007-2018 (2003).
2. Heart Disease and Stroke Statistics - 2003 Update. American Heart Association, Dallas, TX, USA (2003).
3. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
4. Johnson JA, Lima JJ: Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges. Pharmacogenetics 13, 525-534 (2003).
5. Stavroulakis GA, Makris TK, Krespi PG et al.: Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc. Drugs Ther. 14, 427-432 (2000).
6. 1-Adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin. Pharmacol. Ther. 74, 44-52 (2003).
7. Montgomery HE, Keeling PJ, Goldman JH, Humphries SE, Talmud PJ, McKenna WJ: Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 25, 1627-1631 (1995).
8. Liggett SB, Wagoner LE, Craft LL et al.: The Ile164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J. Clin. Invest. 102, 1534-1539 (1998).
9. McNamara DM, Holubkov R, Janosko K et al.: Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103, 1644-1648 (2001).
10. Perez JM, Rathz DA, Petrashevskaya NN et al.: β(1)-Adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat. Med. 9, 1300-1305 (2003).
11. Kaye DM, Smirk B, Williams C, Jennings G, Esler M, Holst D: β-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 13, 379-382 (2003).
12. Terra SG, Hamilton KK, Pauly DF et al.: ARG389Gly β-1 adrenergic receptor polymorphism and left ventricular remodeling changes to β-blocker therapy. Clin. Pharmacol. Ther. 75, P2 (2004).
13. Rose CM, Marsh S, Ameyaw MM, McLeod HL: Pharmacogenetic analysis of clinically relevant genetic polymorphisms. Methods Mol. Med. 85, 225-237 (2003).
14. Rotimi C, Puras A, Cooper R et al.: Polymorphisms of renin-angiotensin genes among Nigerians, Jamaicans, and African Americans. Hypertension 27, 558-563 (1996).
15. Heckbert SR, Hindorff LA, Edwards KL et al.: β2-Adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Circulation 107, 2021-2024 (2003).
16. 2C-adrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 347, 1135-1142 (2002).
17. Materson BJ, Reda DJ, Cushman WC et al.: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N. Engl. J. Med. 328, 914-921 (1993).
18. Yancy CW, Fowler MB, Colucci WS et al.: Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N. Engl. J. Med. 344, 1358-1365 (2001).
19. Domanski M: β-Blocker evaluation of survival trial (BEST). J. Am. Coll. Cardiol. 35, 202A-203A (2000).
20. Agerholm-Larsen B, Tybjserg-Hansen A, Schnohr P, Nordestgaard BG: ACE gene polymorphism explains 30-40% of variability in serum ACE activity in both women and men in the population at ICE: the Copenhagen City Heart Study. Atherosclerosis 147, 425-427 (1999).
21. Torretti J: Sympathetic control of renin release. Annu. Rev. Pharmacol. Toxicol. 22, 167-192 (1982).
22. Pettinger WA, Mitchell HC: Renin release, saralasin and the vasodilator-β-blocker drug interaction in man. N. Engl. J. Med. 292, 1214-1217 (1975).
23. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human β-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch. Pharmacol. 369, 151-159 (2004).
24. Wagoner LE, Craft LL, Singh B et al.: Polymorphisms of the β(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ. Res. 86, 834-840 (2000).
25. Brodde OE, Buscher R, Tellkamp R, Radke J, Dhein S, Insel PA: Blunted cardiac responses to receptor activation in subjects with Thr164Ile β(2)-adrenoceptors. Circulation 103, 1048-1050 (2001).